It’s a wrap on the 2026 Intellus Worldwide Summit. ✅
Three days. Dozens of sessions. One signal that kept repeating:
Pharma insights teams continue to make critical decisions on incomplete patient data. Further, they are actively increasing their use of AI every day.
Here are the 5 moments that stayed with us 👇
Patient voice belongs at the C-Suite table.
Jinky Ang Rosselli (BioCryst) and Scott Cenci (Acadia Pharmaceuticals) made the case for Chief Insights and Chief Data & Insights Officer roles. These leaders don’t just report on patients — they translate patient reality into enterprise decisions.
Behavioral data tells the truth. Attitudinal data tells a story.
Tom Donnelly, Ryan Dicce & Alyssa Klein (iMarketResearch) demonstrated that integrated behavioral segmentation consistently outperforms attitudinal-only approaches. Longitudinal, linked patient-level data is what makes that signal visible.
RWE is only as strong as the patients behind it.
Matthew Heffler (Ipsos) challenged insights professionals to lead — not just support — Real-World Evidence strategy. That requires reaching the patients that the traditional sources miss.
AI governance starts at the data layer.
Casey Horton & Brian Segobiano (Epsilon Life Sciences) unpacked AI washing, IP liability, and an accelerating regulatory gap. Organizations building on clinically grounded, disease-specific AI don’t retrofit compliance — it’s embedded from day one.
Survey fraud now has a shared industry standard.
Michael Wildt and the Intellus Data Integrity Task Force released the first-ever Fraud Guide for market research. Data quality is no longer a differentiator — it’s the baseline the entire industry must hold.
This is exactly why we built Integrated Patient Data™, Medically Smart AI™, Confirmis™, and Clarion™: to reach the rare disease and oncology patients traditional sources miss, surface behavioral truth from linked longitudinal data, and power insights that move at the speed of the business.
